| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Revenue | $17.15B | +39.7% |
| R&D Expense | $92.0M | +10.8% |
| SG&A Expense | $631.0M | +14.5% |
| Interest Expense | $227.0M | -15.0% |
| Pre-tax Income | $1.30B | +86.6% |
| Income Tax | $281.0M | +18.1% |
| Net Income | $954.0M | +304.2% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $1.07B | +7.2% |
| Accounts Receivable | $2.59B | +53.5% |
| Inventory | $3.04B | +57.6% |
| Current Assets | $7.50B | +46.1% |
| Total Assets | $15.10B | +17.2% |
| Current Liabilities | $6.50B | +62.4% |
| Long-term Debt | $4.96B | -13.0% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.14B | +1.4% |
| Investing Cash Flow | -$473.0M | +82.6% |
| Financing Cash Flow | -$615.0M | -441.7% |
| Total Liabilities |
| $12.59B |
| +14.4% |
| Stockholders' Equity | $2.50B | +31.5% |